New Analysis Finds Global Drug Pricing Benchmarking May Fall Short on Affordability
-
Brussels Education Unions Schedule Major November Protest Over Funding and Reforms
-
Crowds Gather at San Francisco Park for Elizabeth Holmes Lookalike Tournament
-
iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury
-
Central Tokyo Apartment Rents Forecast to Rise 11% by 2030
-
Rene Eyre Revisits Autobiographical Performance 'Say A Little Prayer' in London
-
London Museum Granted 24/7 License Ahead of November Opening
-
UAE's HCT Holds Record Graduation and Announces Major Training Expansion
-
Dana White Confirms Flight to Washington for Trump Meeting on Press Secretary Role
-
NASA Awards $10B Lunar Contract Framework to SpaceX, Blue Origin
-
Dengue Fever Expands Into High Himalayas as Climate Change Warms Nepal
-
Katy Perry Tells Fans Ex-Husband Russell Brand 'Should Be in Jail' During UK Concert
-
IoT Refrigerator Hacks Disrupt Blood Labs and Supermarkets Across Europe and US
New Analysis Finds Global Drug Pricing Benchmarking May Fall Short on Affordability
WASHINGTON, D.C. / ACCESS Newswire / February 11, 2026 / A new report by Aimed Alliance, international patient advocates, and advocacy organizations, found that due to the United States' unique health care system, an international reference pricing program, such as those proposed under the Centers for Medicare and Medicaid Services (CMS) GUARD and GLOBE models, may not meaningfully improve affordability for consumers.
Aimed Alliance's new analysis, International Reference Pricing: Lessons Learned from Abroad, reviews prescription drug pricing practices across 23 Organisation for Economic Co-operation and Development (OECD) member countries and incorporates feedback from patients and advocacy organizations with experience engaging drug pricing bodies. The analysis describes how the U.S. health care system provides swift and priority access to novel treatments. The paper also highlights challenges experienced by patients abroad when their perspectives and experiences are not adequately incorporated into value-assessment frameworks.
"Consumers in the United States need prescription drug and health care affordability reforms that address high out-of-pocket costs," said Ashira Vantrees, Director of Legal Strategy & Advocacy at Aimed Alliance. "However, those reforms should be tailored to the U.S. health care supply chain and should not rely on analyses from other countries that have not fairly valued patients' insights and experiences."
The report highlights potential U.S.-based reforms that could more effectively address U.S. health care costs and describes patient-centered best practices in international reference pricing that CMS should adopt if it moves forward with GUARD or GLOBE.
International Reference Pricing: Lessons Learned from Abroad and its executive summary are available on the Aimed Alliance website.
CMS has published notices of proposed rulemaking that provide additional details on the GLOBE and GUARD models. Public comments on implementation of the models in the U.S. are due to CMS by February 23, 2026.
About Aimed Alliance
Established in 2013 and based in Washington, D.C., Aimed Alliance is a not-for-profit health policy organization that works to protect and enhance the rights of healthcare consumers and providers. Aimed Alliance achieves this mission by conducting legal research and analysis; developing sound, patient-centered policy recommendations; and disseminating its findings to inform policymakers and increase public awareness. For more information, visit aimedalliance.org.
Media Contact
Ashira Vantrees, Esq.
[email protected]
SOURCE: Aimed Alliance
View the original press release on ACCESS Newswire
O.Norris--AMWN
